Buccodental side effects of sunitinib in patients with metastatic renal cell carcinoma

BACKGROUND: Sunitinib is a tyrosine kinase inhibitor approved for the treatment of renal cell carcinoma (RCC). Few data evaluated severe buccodental adverse events. The aim of this study was to evaluate sunitinib buccodental toxicity in patients with metastatic RCC and to compare it with that of sta...

Descripción completa

Detalles Bibliográficos
Autores principales: Gilabert, M, Provansal, M, Cappiello, M, Walz, Y, Salem, N, Tarpin, C, Brunelle, S, Thomassin, J, Gravis, G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3790170/
https://www.ncbi.nlm.nih.gov/pubmed/24045668
http://dx.doi.org/10.1038/bjc.2013.516

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3790170/
https://www.ncbi.nlm.nih.gov/pubmed/24045668
http://dx.doi.org/10.1038/bjc.2013.516

Ejemplares similares